Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)

The safety information of brolucizumab primarily comes from clinical trials experience. This study aimed to explore the ocular and systemic adverse events (AEs) associated with brolucizumab among real-world patients through data mining the FDA Adverse Event Reporting System (FAERS) database.